September 15th 2022 : Newsletter Successful nasal drug delivery of dry powder formulations requires a delivered dose that can penetrate beyond the nasal entrance region and deposit in the peripheral nasal cavity, whilst avoiding deeper penetration to the airways of the lungs. This delivery, or deposition pattern, is determined by the aerodynamic particle size of … Read more
August 16th 2022 : Newsletter Successful MHRA Inspection Upperton is delighted to announce that during the last week of July 2022 the UK MHRA conducted a routine, three day inspection of the GMP facility and Quality Control testing laboratories following which, no Critical or Major observations were raised. Speaking after the inspection, CEO Nikki Whitfield … Read more
June 23rd 2022 : Newsletter The benefits of powder characterisation When developing products containing spray dried powders it is vital that the physical properties of the powders produced are determined. The physical properties of spray dried powders provides important information that can assist during the pre-formulation screening and early process development phases since these properties … Read more
23rd May 2022 : Press Release Upperton Pharma Solutions (Upperton), a UK-based specialist contract development and manufacturing organisation (CDMO), has announced a circa. £15m investment into the design and build of a 50,000 sq ft facility in Nottingham. The new facilities will allow a significant increase in research and development laboratory space and a 10-fold … Read more
5th April 2022 – Press Release Nottingham-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions, has launched a unique nasal delivery development platform, UpperNose™, to make it easier and faster for small and mid-sized innovators to access the knowledge and capabilities necessary for the successful development of nasal dosage formulations. Drug developers seeking to … Read more
Article 20th May 2021 – Upperton Nasal Delivery Article Published in ONdrugDelivery Formulation Options In Nasal Drug Delivery Upperton had an article published in Edition 119 ONdrugDeliver in May 2021 In the article Richard Johnson, CEO and founder of Upperton, discusses the advantages of nasal delivery and why there is growing interest in this route … Read more
News 29th April 2021 – Formulation Options in Nasal Drug Delivery Nasal delivery offers a number of unique opportunities for the successful delivery of drugs and vaccines either locally, systemically or directly to the central nervous system. This utility has resulted in growing interest from scientists looking to administer both therapeutic agents and vaccines via … Read more
News 25th March 2021 – Formulation Options in Nasal Drug Delivery The anatomy and physiology of the nasal cavity creates a number of unique opportunities for the successful delivery of drugs and vaccines. This can be locally, systemically or directly to the central nervous system. This utility has resulted in growing interest from scientists looking to … Read more
The anatomy and physiology of the nasal cavity creates a number of unique opportunities for the successful delivery of drugs and vaccines. This can be locally, systemically or directly to the central nervous system. This utility has resulted in growing interest from scientists looking to administer both therapeutic agents and vaccines via the nasal delivery … Read more
News 1st December 2020 – Manufacturing Clinical Supplies: The Early Phase Clinical Manufacture Timeline Whilst undergoing research and development on a new chemical entity / new biological entity there are major initial objectives when planning the roadmap to clinic, submission and approval of the regulatory documentation, and ultimately dosage form administration in a human clinical … Read more
Albert Einstein Centre, Nottingham Science Park, Nottingham, UK NG7 2TN,
Phone: +44 (0) 115 855 7050
Email: contact@upperton.com
Copyright © 2024 Upperton Limited. All rights reserved.
